Rapport Therapeutics’ (RAPP) “Buy” Rating Reiterated at HC Wainwright

Rapport Therapeutics (NASDAQ:RAPP)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $66.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 122.95% from the company’s previous close.

Other research analysts also recently issued research reports about the company. Wall Street Zen downgraded Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a research note on Tuesday. Wolfe Research initiated coverage on Rapport Therapeutics in a report on Thursday, October 15th. They issued an “outperform” rating and a $50.00 price objective for the company. Leerink Partners began coverage on shares of Rapport Therapeutics in a research report on Wednesday, June 24th. They set an “outperform” rating and a $52.00 target price on the stock. Finally, William Blair assumed coverage on shares of Rapport Therapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Rapport Therapeutics presently has a consensus rating of “Buy” and an average price target of $65.00.

Rapport Therapeutics Trading Up 3.5%

NASDAQ:RAPP traded up $1.00 during midday trading on Tuesday, hitting $29.60. 5,748,354 shares of the company were exchanged, compared to its average volume of 380,280. Rapport Therapeutics has a fifty-two week low of $23.75 and a fifty-two week high of $52.93. The company has a market capitalization of $1.42 billion, a PE ratio of -9.75 and a beta of 1.22. The company has a fifty day simple moving average of $40.70 and a 200 day simple moving average of $39.14.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, equities research analysts expect that Rapport Therapeutics will post -4.09 EPS for the current year.

Insider Activity

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 28,958 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the completion of the sale, the chief executive officer directly owned 486,108 shares of the company’s stock, valued at $23,338,045.08. This represents a 5.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Cheryl Gault sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $33.19, for a total value of $331,900.00. Following the sale, the chief operating officer directly owned 139,914 shares of the company’s stock, valued at approximately $4,643,745.66. This represents a 6.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 97,976 shares of company stock worth $4,420,349 in the last 90 days. 12.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Rapport Therapeutics

Several large investors have recently modified their holdings of RAPP. TRV GP V LLC purchased a new position in Rapport Therapeutics during the 2nd quarter worth $261,709,477. ARCH Venture Management LLC acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter worth $155,376,512. BlackRock Inc. purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at about $112,500,000. Johnson & Johnson purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at about $74,360,823. Finally, TRV GP VI LLC purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at about $40,387,314.

Trending Headlines about Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 trial endpoints. The study showed statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score and CGI-BP Severity of Mania score, supporting the drug’s potential efficacy. Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial
• Positive Sentiment: The results increase confidence in RAP-219’s commercial potential. Jefferies estimates the bipolar-mania indication could represent a potential $1 billion peak-sales opportunity, making the trial success particularly important for investor expectations. Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging
• Positive Sentiment: Analysts became more bullish. BTIG Research raised its price target from $75 to $89 and maintained a Buy rating. Wells Fargo also reiterated its Buy rating, adding further positive momentum. Wells Fargo Sticks to Its Buy Rating
• Positive Sentiment: Trading volume surged. Premarket volume was substantially above the stock’s typical activity, indicating strong investor attention following the clinical update. Why Is Rapport Therapeutics Stock Trading Higher Today?
• Neutral Sentiment: The results are topline Phase 2 data, so additional analysis, regulatory review, and later-stage testing remain necessary before commercialization.
• Negative Sentiment: Before the trial announcement, commentary described RAPP as potentially expensive after a substantial monthly decline, highlighting valuation risk if follow-up data or regulatory progress disappoints. Rapport Therapeutics Stock Seems Pricey Following a Monthly Slide

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system.

Rapport’s lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy.